Thursday, Nov. 29
8 – 11a.m. EST
Hosted by: Hogan Lovells, Washington D.C.

As the Trump administration prepares to enter its third year, one thing has become clear — drug pricing is an issue that will not go away. Polls have consistently shown that voters believe high drug costs should be a top priority on Capitol Hill — and Democrats, soon to be the majority party in the House, have indicated that drug pricing reforms will be one of their first legislative priorities.

Please log in to register for this subscriber-only event. Not yet a subscriber? Subscribe now to register for this event.


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy